Lipidor AB Announces Last Patient Has Been Enrolled in the Ongoing Phase III Study of AKP02 Against Mild to Moderate Psoriasis
The psoriasis candidate AKP02 combines calcipotriol and betamethasone dipropionate and is based on Lipidor's patented AKVANO® technology. Lipidor has chosen to compare the sprayable drug candidate AKP02 with Enstilar, which is one of the market-leading preparations for topical treatment of psoriasis. AKP02 contains the same combination of active substances as Enstilar. The trial is conducted by Cadila Pharmaceuticals, which successfully completed the Phase III study of Lipidor's monotherapy product AKP01 containing calcipotriol alone.
Positive results from the study generate a milestone payment in accordance with the licence agreement signed in 2021 with RELIFE S.r.l., a company in the Menarini Group, for Europe, the CIS countries and Turkey.